Faeth Therapeutics
NASDAQ: FTHAustin, US · Delaware corporation · 42 employees on LinkedIn · 11 known investors
Find your way into Faeth Therapeutics
300 people in our graph share verified history with the Faeth Therapeutics team — schools, employers, funds. One of them is your warm intro.
Patrick Norrisunlockedknows Oliver Maddocks · together at The University of Edinburgh (overlapped)
knows the team · via The University of Edinburgh
×8knows the team · via New York University School of Law
×2knows the team · via Cardiff University / Prifysgol Caerdydd
Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway. Its lead candidate, PIKTOR, is an all-oral combination targeting PI3K-alpha, mTORC1, and mTORC2 for cancers including endometrial and HR+/HER2- breast cancer.
Founders & leadership
AP
Anand ParikhinCo-founderFounder and CEO of Faeth Therapeutics, a clinical-stage oncology company developing therapies targeting the PI3K/AKT/mTOR pathway for cancers including endometrial and HR+/HER2- breast cancer.
OM
Oliver MaddocksinCo-founderOliver Maddocks is an Executive Officer and Director at Faeth Therapeutics, a clinical-stage oncology company developing therapies targeting the PI3K/AKT/mTOR pathway. He has research expertise in cancer metabolism and translational oncology.
Board
AM
JD
Jayson DallasBoard director
RG
Robert GouldBoard director
SH
Stephen HahnBoard director
Investors · 11
Able PartnersNew York · $500K – $3M
Atacama VenturesSan Francisco
Cota CapitalSan Francisco
Future VenturesLos Altos · $1M – $10M
iSelect FundSt. Louis · $250K – $2M
S2G InvestmentsChicago · $1M – $5M
AgFunderreportedSan Francisco · $10K – $5M
Cantos VenturesreportedSan Francisco · $400K – $1.5M
Digitalis VenturesreportedNew York · $100K – $10M
KdT VenturesreportedAustin · $500K – $3M
Khosla VenturesreportedMenlo Park · $5K – $50Mvia Alex Morgan · board
Reported raises · per SEC filings
Form D private placements$24.4M disclosed across 1 round · 2025
▶$24.4MraisedJan 2026 · 35 investors · BiotechnologyRule 506(b)
▶$24.4MraisedJan 2026 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jayson DallasDirector
- Anand ParikhExecutive Officer, Director, Promoter
- Alex MorganDirector
- Robert GouldDirector
- Stephen HahnDirector
- Oliver MaddocksExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $24.4M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapFate Therapeutics20 shared keywordsFate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer. The company is conducting clinical trials on product candidates under strict regulatory and ethical standards.
Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Faeth Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Faeth Therapeutics do?
- Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway. Its lead candidate, PIKTOR, is an all-oral combination targeting PI3K-alpha, mTORC1, and mTORC2 for cancers including endometrial and HR+/HER2- breast cancer.
- Who founded Faeth Therapeutics?
- Faeth Therapeutics was founded by Anand Parikh, Oliver Maddocks.
- Who are Faeth Therapeutics's investors?
- Faeth Therapeutics's investors include Able Partners, Atacama Ventures, Cota Capital, Future Ventures, iSelect Fund, S2G Investments, AgFunder, Cantos Ventures and 3 more.
- How much funding has Faeth Therapeutics raised?
- Faeth Therapeutics has disclosed $24.4M raised across 1 round.
- Where is Faeth Therapeutics headquartered?
- Faeth Therapeutics is headquartered in Austin, US.